Principal Health EconomistHCD EconomicsKnutsford, England, United Kingdom
PB0250 - Exploring clinical profile and patient-reported outcomes of people with non-inhibitor severe hemophilia A: insights from the Spanish cohort of ‘Cost Haemophilia: Socioeconomic Survey’ (CHESS)
Sunday, June 23, 202413:45 – 14:45 ICT
PB0259 - Relationship between current and historic clinical characteristics and bleeding outcomes in people with severe Haemophilia A on emicizumab: a multivariate analysis of data from the CHESS studies
PB0502 - Clinical outcomes in patients with hemophilia A receiving octocog alfa or rurioctocog alfa pegol versus other FVIII replacement therapies: Insights from the AHEAD, CHESS II, and CHESS PAEDs studies
Monday, June 24, 202413:45 – 14:45 ICT
PB0549 - Physical activity engagement and health-related quality of life in patients with hemophilia A receiving either octocog alfa or rurioctocog alfa pegol versus other FVIII replacement therapies
